VOLUME 116, ISSUE 4, P936-942
Authors:
Paul Pirtea, M.D., Jean Marc Ayoubi, M.D., Ph.D., Stephanie Desmedt, M.D., Ph.D., Guy T’Sjoen, M.D., Ph.D.
Abstract:
Gender-affirming hormone therapy (GAHT) is often provided to transgender people. In this review of the literature, the current knowledge of ovarian, breast, and metabolic changes (body composition, insulin resistance, bone density, cardiovascular risk factors such as lipids, blood pressure, and hematocrit) observed following GAHT in adult transgender men is discussed.